Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
Want to see AU:CYP full AI Analyst Report?
CYP Stock Chart & Stats
AU$0.29
-AU$0.01(-4.17%)
At close: 4:00 PM EST
AU$0.29
-AU$0.01(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.15 - AU$0.44
Previous CloseN/A
Volume63.41K
Average Volume (3M)233.82K
Market Cap
AU$86.67M
Enterprise ValueAU$80.52M
Total Cash (Recent Filing)AU$5.05M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding237,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$8.55M
Bulls Say, Bears Say
Bulls Say
Scalable Allogeneic PlatformCynata’s iPSC-derived allogeneic MSC platform provides a structural manufacturing advantage versus autologous approaches: off-the-shelf products enable consistent batch quality, lower per-dose manufacturing complexity and the potential to scale supply cost-effectively, supporting durable commercial options if clinical success follows.
Debt-free Balance SheetZero reported debt reduces insolvency and interest-cost risk, preserving strategic optionality. For a clinical-stage biotech this lowers near-term financing stress, allowing management to prioritize R&D and partnerships rather than servicing debt, improving long-term flexibility to advance trials or negotiate collaborations.
High Gross Margin PotentialReported near-100% gross margin reflects the product-like economics of cell therapy IP and services; if volume scales, incremental revenues would flow largely to the bottom line. This structural margin profile supports long-term profitability potential once fixed R&D and SG&A are controlled.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow indicates ongoing reliance on external financing to fund trials and operations. Over 2–6 months this structural cash burn raises dilution and execution risk, constraining the pace of development and increasing sensitivity to capital markets or partner funding timelines.
No Recurring Product RevenueAs a clinical-stage biotech without commercial products, Cynata depends on equity raises, milestones or grants. This business model creates structural revenue uncertainty and timing risk; sustained value creation requires successful trials, approvals or durable partner licensing to establish repeatable cash flows.
Large Ongoing Losses And Declining EquityMaterial declines in equity and assets alongside persistently large operating losses show shareholder capital is being consumed. Over the medium term this pressures funding needs and can limit reinvestment options, making long-term program execution and valuation sensitive to trial outcomes and capital access.
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was AU$0.14 and its highest was AU$0.43 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is AU$86.67M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 128 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 237,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
-179.37%
Trailing 12-Months
Asset Growth
-62.21%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Limited (CYP) is an Australian biotechnology company focused on the development and commercialization of innovative stem cell therapies. The company specializes in Cymerus™, a proprietary technology for manufacturing mesenchymal stem cells (MSCs) at scale. This platform enables the production of therapeutic stem cells without the limitation of donor availability, supporting the treatment of various diseases and medical conditions. Cynata's core products target applications in regenerative medicine, encompassing indications such as cardiovascular disease, respiratory ailments, and graft-versus-host disease (GvHD).
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―